Breast CSCs are intrinsically sensitive to genetic and epigenetic modifications, and epigenetic-based therapies may significantly impact their behavior. Further research is needed on DNMT and HDAC co-inhibition in refractory or drug-resistant breast cancer. The gene discussed is HDAC9; the disease is breast cancer.